Interstitial Cystitis Drugs Market is Segmented By Type (Nonsteroidal anti-inflammatory drugs, Tricyclic antidepressants, Antihistamines, Pentosan polysulfate sodium (Elmiron), Dimethyl sulfoxide (DMSO), Hyaluronic acid (Cystistat), Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Interstitial Cystitis Drugs Market Overview
Interstitial Cystitis Drugs Market is estimated to reach at a CAGR 5.28% during the forecast period (2024-2031).
Interstitial cystitis is a persistent illness that causes pressure in the bladder and bladder and pelvic pain. The soreness might range from minor to severe. The disorder is part of the painful bladder syndrome range of diseases. Although there's no cure, medications and other therapies may offer relief.
Interstitial Cystitis Drugs Market Dynamics
Increasing Investigational treatments for the treatment of BPS/IC is expected to drive market growth.
The plasma membrane contains most of the transient receptor potential (TRP) channels. They are in charge of transporting calcium, magnesium, and metal ions across the cell membrane. Many physiological systems, including sensory functions (pain and heat perception), hemostatic functions, vasomotor activities, and muscular contraction, rely on it. For instance, Intravesical capsaicin therapy has been used effectively to treat detrusor overactivity (DOA) in patients with neurogenic bladder.
Moreover, the recent innovation of specialized financing programs to assist rare illness research has the potential to boost basic scientific and clinical research in this field. Rather than research on more common diseases that the scientific community is more familiar with, rare illness research has been recognized as requiring unique research approaches such as data gathering, data processing, and international collaborations. Thus, the market is expected to drive in the forecast period from the above statements.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The coronavirus, or COVID-19, the outbreak began in Wuhan, China, and has now expanded across continents, affecting a wide range of businesses. IC's persistent pain feelings caused by IC have been linked to psychological issues like anxiety and sadness. Furthermore, the COVID-19 epidemic exacerbated IC patients' distress by inducing psychological symptoms such as dread, despair, boredom, frustration, and anger. A multidisciplinary approach provides tailored treatment for IC patients by delivering a web-mediated counseling intervention for patients and their caregivers. This may support a relationship-based reform process that improves one's quality of life.
Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.
Interstitial Cystitis Drugs Market Segment Analysis
Dimethyl sulfoxide (DMSO) segment is expected to hold the largest market share in interstitial cystitis drugs market
The dimethyl sulfoxide (DMSO)segment is expected to dominate in 2021. The segment benefits because it is the latest treatment for interstitial cystitis, and it is believed to reduce swelling and pain due to interstitial cystitis. It may improve blood supply to the treated area. Moreover, On 4th November 2021, the US Food and Drug Administration (FDA) approved Dimethyl sulfoxide (DMSO) to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Therefore, it has increased the demand for the drug. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Interstitial Cystitis Drugs Market
| Metrics | Details |
| Market CAGR | 5.28% |
| Segments Covered | By Type, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Interstitial Cystitis Drugs Market Geographical Analysis
North America region holds the largest market share in the global interstitial cystitis drugs market
In 2021, North America accounted for the highest revenue share. The increasing prevalence of interstitial cystitis, rise in research funding, advances in interstitial diagnostic imaging of interstitial cystitis and high adoption of interstitial cystitis drugs in the region are some of the factors the market is expected to boost in the forecast period. For instance, Interstitial cystitis (IC) is common in the U.S. was reported to be 5,894,905 in 2018. In contrast, the condition may affect between 3 million and 8 million women and between 1 million and 4 million men in the United States in 2020. Moreover, recent bladder wall and brain MRI developments could revolutionize our understanding and treatment of people with IC/BPS. T1-weighted MRI and fMRI with high resolution can reveal abnormalities in central processing in persistent pelvic discomfort. CE-MRI of the bladder wall can objectively distinguish three distinct IC/BPS entities pelvic hypersensitivity, IC/BPS, and IC/BPS with Hunner's lesions. Such objective classification can help doctors choose the right patients for medications that target chronic inflammation in the bladder wall and lessen the dependence on subjective results to predict the efficacy and safety of new treatments. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Interstitial Cystitis Drugs Market Competitive Landscape
Major key players in the interstitial cystitis drugs market are Perrigo Company plc., Bayer HealthCare LLC, GlaxoSmithKline (GSK), Inc., Janssen Pharmaceuticals, Inc., Mallinckrodt Inc., FemmePharma Consumer Healthcare, Tyros Biopharma Inc. and Sandoz Inc.
Janssen Pharmaceuticals, Inc..:
Overview:
Janssen Pharmaceuticals is a completely owned subsidiary of Johnson & Johnson with headquarters in Beerse, Belgium. Paul Janssen launched the company in 1953. It works on mental disease, neurological problems, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies, and cancer, among other things. The Johnson & Johnson Company Ortho-McNeil-Janssen group now includes Janssen and Ortho-McNeil Pharmaceutical.
Product Portfolio:
ELMIRON (pentosan polysulfate sodium): ELMIRON is a prescription medicine that treats bladder pain or discomfort associated with interstitial cystitis.
